Featured Research

from universities, journals, and other organizations

Vaccine used to treat cervical precancers triggers immune cell response

Date:
January 29, 2014
Source:
Johns Hopkins Medicine
Summary:
Preliminary results of a small clinical trial show that a vaccine used to treat women with high-grade precancerous cervical lesions triggers an immune cell response within the damaged tissue itself. The scientists who conducted the trial said the finding is significant because measuring immune system responses directly in the lesions may be a more accurate way to evaluate so-called “therapeutic” vaccines than by the conventional means of blood analysis.

Stages of cervical cancer.
Credit: Emily Shaw

Preliminary results of a small clinical trial show that a vaccine used to treat women with high-grade precancerous cervical lesions triggers an immune cell response within the damaged tissue itself. The Johns Hopkins scientists who conducted the trial said the finding is significant because measuring immune system responses directly in the lesions may be a more accurate way to evaluate so-called "therapeutic" vaccines than by the conventional means of blood analysis.

"It's difficult to measure immune cell responses to therapeutic vaccines, but we believe that clinical studies could tell us more about the value and function of the vaccines if we check for the response in the lesions, where the immune system is fighting precancerous cells," says Connie Trimble, M.D., associate professor of gynecology and obstetrics, oncology and pathology at Johns Hopkins' Kimmel Cancer Center.

Results of the first 12 women enrolled at Johns Hopkins on a clinical trial led by Trimble are reported online in the Jan. 27 issue of Science Translational Medicine. Each of the women was diagnosed with high-grade precancerous cervical lesions linked to a strain of the human papillomavirus (HPV16) most commonly associated with cervical cancer. In a bid to treat the lesions and prevent cervical cancer, they received three vaccine injections in the upper arm over an eight-week period.

Two types of vaccines were used for the study: one constructed with genetically engineered DNA molecules that teach immune system cells to recognize premalignant cells expressing HPV16 E7 proteins, and one that is a non-infectious, engineered virus that targets and kills precancerous cells marked by HPV16 and HPV18 E6 and E7 proteins.

Seven weeks after the third vaccination, the investigators surgically removed cervical lesions from all of the women. Blood samples and cervical tissue were collected from each patient at the beginning and end of the trial, letting scientists compare immune cell responses before and after vaccination.

In three of six patients treated with the highest dose of the vaccine, and one patient in each of the two groups receiving lower doses of the vaccine, the cervical lesions disappeared. The first patient was treated in 2008, and the 12th in 2012. None of the 12 patients has, so far, developed more lesions.

Among those vaccinated, the investigators found significant increases of CD8 T-cells, the "killer" cells of the immune system, in cervical tissue. Blood samples failed to show as strong a pre- and postvaccination effect. The investigators also said the vaccine did not have the unwanted consequence of altering the number of T-regulatory cells, which suppress immune system responses.

"We found striking immune system changes within cervical lesions, which were not as evident in the patients' peripheral blood samples," says Trimble.

The investigators also measured gene expression of postvaccinated cervical cells in three of the patients and found increased expression of several genes (CXCR3, Tbet and IFNβ) associated with activation of the immune system. They found many similarities in T-cell receptors in the cervical tissue of two of the vaccinated patients, "suggesting that the T-cells are seeing the same thing," says Trimble.

The Johns Hopkins team says it plans to enroll some 20 more patients, testing a combination of the vaccines and a topical cream to enhance the immune response locally.

Trimble explains that the location of cervical lesions gives scientists an advantage in their vaccination approach. "It's important that we can monitor these cervical lesions closely," says Trimble.

She says that the conventional practice of measuring vaccine effectiveness via blood tests probably began with mouse models used for immunotherapy research. "But the way that HPV and the immune system behave in humans may be far different," she says.

HPV causes nearly all cervical, anal, vaginal, and penile cancers and nearly two-thirds of oral cancers. In the cervix, about 20 to 25 percent of high-grade lesions will disappear spontaneously. Because there is no standard way to predict lesions that will disappear, the current standard of care for these lesions is surgical removal. Current preventive vaccines for HPV are not effective on women already exposed to the ubiquitous virus.


Story Source:

The above story is based on materials provided by Johns Hopkins Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. L. Maldonado, J. E. Teague, M. P. Morrow, I. Jotova, T. C. Wu, C. Wang, C. Desmarais, J. D. Boyer, B. Tycko, H. S. Robins, R. A. Clark, C. L. Trimble. Intramuscular Therapeutic Vaccination Targeting HPV16 Induces T Cell Responses That Localize in Mucosal Lesions. Science Translational Medicine, 2014; 6 (221): 221ra13 DOI: 10.1126/scitranslmed.3007323

Cite This Page:

Johns Hopkins Medicine. "Vaccine used to treat cervical precancers triggers immune cell response." ScienceDaily. ScienceDaily, 29 January 2014. <www.sciencedaily.com/releases/2014/01/140129150730.htm>.
Johns Hopkins Medicine. (2014, January 29). Vaccine used to treat cervical precancers triggers immune cell response. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/01/140129150730.htm
Johns Hopkins Medicine. "Vaccine used to treat cervical precancers triggers immune cell response." ScienceDaily. www.sciencedaily.com/releases/2014/01/140129150730.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins